Internal Medicine, Hematology & Oncology · Newnan, GA
NPI
1730147596
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
775 Poplar Rd Ste 310
Newnan, GA, 30265
Phone (770) 251-2590
Groups this clinician bills Medicare through
Medicare paid, 2024
$5.7M
243,465 services
Medicare patients, 2024
830
Average age 75
Drug cost, 2024
$11.8M
3,558 prescriptions
Company payments, 2025
$3,229
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vasileios J Assikis was code J9299 (injection, nivolumab, 1 mg), 33,400 times for 15 patients. In total Vasileios J Assikis billed 243,465 services in 143 codes, and Medicare paid $5.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-08-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9299 Injection, nivolumab, 1 mg | Office | 33,400 | 15 | $22.01 | $735K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 28,600 | 27 | $42.11 | $1.2M |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 16,800 | 13 | $2.19 | $37K |
| J0897 Injection, denosumab, 1 mg | Office | 14,640 | 56 | $19.45 | $285K |
| J9267 Injection, paclitaxel, 1 mg | Office | 8,446 | 21 | $0.08 | $643 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 3,100 | 30 | $14.90 | $46K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,535 | 62 | $0.08 | $214 |
| Q5112 Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg | Office | 2,244 | 11 | $26.55 | $60K |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 2,039 | 11 | $28.88 | $59K |
| J9395 Injection, fulvestrant, 25 mg | Office | 1,420 | 11 | $5.61 | $7,966 |
| 85025 Blood Count | Office | 1,242 | 440 | $7.49 | $9,307 |
| 99213 Office E&M - Established | Office | 694 | 382 | $56.31 | $39K |
| 96413 Chemotherapy Administration | Office | 692 | 143 | $85.46 | $59K |
| 99214 Office E&M - Established | Office | 670 | 263 | $85.83 | $58K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 480 | 18 | $0.63 | $303 |
By year: 2022 $4.4M for 184,252 services; 2023 $6.1M for 268,649 services; 2024 $5.7M for 243,465 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,242 | 440 | $7.49 | $9,307 |
| 81002 Clinical Chemistry | 30 | 15 | $3.41 | $102 |
Medicare prescription drug claims, 2024
In 2024, the drug Vasileios J Assikis prescribed most often to Medicare patients was Abiraterone Acetate, with 284 prescriptions and refills. In total Vasileios J Assikis wrote 3,558 Medicare prescriptions that cost $11.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Abiraterone Acetate Generic | 284 | 288 | 34 | $570K |
| Prednisone Generic | 211 | 314 | 61 | $1,242 |
| Anastrozole Generic | 171 | 464 | 58 | $3,084 |
| Xtandi Enzalutamide | 144 | 144 | 17 | $1.6M |
| Lupron Depot Leuprolide Acetate | 134 | 390 | 51 | $808K |
| Erleada Apalutamide | 119 | 120 | 12 | $1.6M |
| Eliquis Apixaban | 109 | 119 | 18 | $72K |
| Ondansetron Odt Ondansetron | 105 | 109 | 64 | $1,654 |
| Alendronate Sodium Generic | 93 | 248 | 28 | $970 |
| Letrozole Generic | 89 | 209 | 27 | $2,014 |
| Oxycodone Hcl Generic | 87 | 87 | 31 | $2,159 |
| Revlimid Lenalidomide | 85 | 85 | Under 11 | $1.4M |
| Nubeqa Darolutamide | 82 | 82 | Under 11 | $988K |
| Prochlorperazine Maleate Generic | 81 | 82 | 62 | $1,294 |
| Tamoxifen Citrate Generic | 69 | 156 | 23 | $1,517 |
Brand drugs: - claims; generic drugs: 2,468 claims; opioid claims: 238.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vasileios J Assikis $3,229 ($1,959 in general payments such as food, travel and fees and $1,270 for research) from 24 companies. The largest payer was Pfizer Inc. with $1,342.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 6 | $1,342 |
| Janssen Biotech, Inc. JNJ | 1 | $1,010 |
| Abbvie Inc. ABBV | 10 | $220 |
| Taiho Oncology, Inc. 4578.T | 3 | $102 |
| Eisai Inc. 4523.T | 2 | $59.17 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 2 | $57.68 |
| Merck Sharp & Dohme LLC MRK | 2 | $56.11 |
| Array Biopharma Inc PFE | 3 | $35.86 |
| Gilead Sciences, Inc. GILD | 1 | $33.08 |
| Stemline Therapeutics Inc. | 1 | $31.84 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.